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Measurements of Biogenic Amines and Metabolites 
in the CSF of Suicide Victims and Nonsuicides 
G . KAUERT, T . ZUCKER, T . G I L G , and W. EISENMENGER 
Introduction 
In 1983 we started a study by measuring biogenic amines in postmortem CSF 
from suicide victims and nonsuicides. What prompted us to do that? The rea-
sons first were of a practical nature: In forensic medicine one of the main pur-
poses is the detection of causes of death. However, in many cases there are no 
anatomic or morphological signs. Especially for those cases in which a differen-
tiation between suicide and accident or homicide is not possible, other di-
agnostic criteria must be found. The monoamine hypothesis of the pathogenesis 
of depressive disorders and particularly the findings of decreased 5-hydroxy-
indoleacetic acid (5-HIAA) levels in lumbar CSF of depressive suicidal patients 
(Asberg et al. 1976) prompted us to assess Serotonin (5-HT) and other bio-
genetic amines in the postmortem CSF to look for quantitative differences in 
suicides and controls regardless of mental disorders. For detailed reviews about 
biological factors of suicidal behavior see Asberg et al. (1986). 
Analyzing the amines or neurotransmitters themselves instead of their 
acidic and neutral metabolites has practical reasons: We have a routine method 
for detecting biogenic amines simultaneously from biological fluids and tissues 
(Kauert 1986). Up to now measurements of biogenic amines in postmortem 
CSF have not been performed. 
Methods 
Sampling of CSF from the Corpse 
The CSF samples were taken during legal autopsies. To obtain cranial CSF, the 
calvarium was opened, the chiasma opticum carefully cut avoiding injury to the 
arteriae carotis internae, the brain then slightly lifted, and with a long cannulat-
ed syringe CSF aspirated from the subarachnoid space in the area of the cis-
terna interpeduncularis and downward at the height of the pons (Fig. 1 a, b). 
We could not perform suboccipital puncture for forensic reasons. 
The lumbar puncture was performed by ventral Perforation of the in-
tervertebral disk L3/L4 or L4/L5 after removal of the intestinal tract (Fig. 1 c). 
The volume of CSF ranged from 2 to 6 ml. The samples were kept frozen at 
-20° C until analysis. 
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A nalyses 
The isolation of biogenic amines from CSF consists of a combined ion 
exchange and derivatization step. In general, we took 2 ml of CSF and used 
etilefrine as an internal Standard for quantification. The derivatives formed 
were detected by capillary gas chromatography mass spectrometry using an am-
monia chemical ionization mode to get intensive quasi molecular ions for mul-
tiple ion detection (Fig. 2). 
For more detailed description of the analytical procedure see Kauert 1986. 
Casuistics 
The causes of death for the controls and the modes chosen for suicide are listed 
in Table 1 according to the frequency of the number of cases in which we ob-
tained cranial plus lumbar or cranial CSF alone. 
Table 1. Frequency with which cranial plus lumbar CSF or 
cranial CSF alone was obtained 
No. of cases 
Cranial Lumbar 






















Methods chosen for suicide 
Hanging atypical 
Hanging typical 
Cutting of wrist arteries 
Shooting 
Falling from height 
Drowning 
Suffocation (plastic bag) 
Drug overdose 
Cyanide intoxication 




















254 G. Kauert et al. 
Measurements of Biogenic Amines and Metabolites in the CSF 255 
Fig. 1 c 
Fig. 1 a - c . Technique of cra-
nial puncture of CSF after 
opening of the scull (a, b) and 
technique of lumbar puncture 
of CSF (c) 
C S F 6 2 3 1 8 + s u b o c c i p i t a l 
Fig. 2. Mass fragmentogram of 
biogenic amine derivatives 
isolated from CSF. 5-HT, 
Serotonin; 3-MT, methoxytyr-
amine; DA, dopamine; NM, 
normetanephrine; M, meta-
nephrine; NE, norepinephrine; 
E, epinephrine 
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Table 2 a. Parameters of cases with 5-HT determination in cranial CSF 
Controls Suicides P 
Age ÄVSD 51.9/20.1 51.3/18.9 NS 
(yrs) ränge 6 - 8 5 2 6 - 9 5 
n 27 46 
Body weight ÄVSD 64.9/15.3 63.2/12.5 NS 
(kg) ränge 24.0-86.3 43.5-88.8 
n 36 46 
Body height Ä/SD 168.4/11.4 167.4/9.6 NS 
(cm) ränge 126-186 145-185 
n 36 45 
Postmortem delay Ä/SD 44.6/29.6 31.8/19.9 <.05 
(h) ränge 3 - 1 2 2 5 .5 -88 
n 37 45 
Ethanol in blood Ä/SD 0.29/0.61 0.56/0.96 NS 
(%o) ränge 0.0-1.98 0 .0-3 .06 
n 37 45 
Table 2 b. Parameters of cases with 5-HT determination in cranial CSF 
Controls Suicides P 
Age ÄVSD 42.9/20.5 46.9/16.6 NS 
(yrs) ränge 6 - 8 5 2 5 - 9 5 
n 13 22 
Body weight ÄVSD 61.4/16.7 64.3/10.4 NS 
(kg) ränge 24.0-78.3 44.7-88.8 
n 12 22 
Body height ÄVSD 167.3/15.0 168.5/7.9 NS 
(cm) ränge 126-186 145-185 
n 12 22 
Postmortem delay ÄVSD 45.1/34.7 38.3/26.8 <.05 
(h) ränge 3 - 1 2 2 5 .5 -88 
n 13 22 
Ethanol in blood ÄVSD 0.39/0.67 0.68/0.99 NS 
(%o) ränge 0.0-1.75 0.0-2.81 
n 7 9 
In the controls about half of the cases derived from cardiac failures and in 
the suicides the largest group were due to atypical hanging. Besides other 
violent methods, we also included cases from drug overdoses as well as intoxi-
cations by poisons such as Cyanide, carbon monoxide, or organophosphates. 
A comparison of the demographic data in suicide victims and controls 
separated according to cranial and lumbar 5-HT determinations is demon-
strated in Table 2 a, b. 
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Results 
The most striking findings among the amines investigated showed 5-HT both in 
cranial and lumbar CSF (Fig. 3). In suicides the 5-HT levels were significantly 
increased by a mean factor of about 3 for both cranial and lumbar CSF. 
The data available from the literature for basal 5-HT levels in lumbar CSF 
are very inconsistent, obviously because of different analytical methods em-
ployed. The most probable level is in a ränge of 1 ng/ml. The distribution of 
frequency of 5-HT levels is demonstrated in Fig. 4. In cranial CSF there was a 
rather broad oveiiapping of values between suicides and controls, but we found 
that 50% of the values of the controls showed levels lower than 10 ng/ml and 
only 15% of the suicide values were within this ränge. 
Moreover, there was no case of suicide below the 5-ng limit. The relative 
frequency of distribution of 5-HT levels in lumbar CSF is plotted in Fig. 5. 
Again we found a simular Situation compared with the cranial 5-HT levels: 
about 50% of the control values were below the 5-ng limit, and no case of sui-
cide could be found there. 
The other amines which we analyzed, i.e., dopamine, epinephrine, 
norepinephrine, and the 3-methoxy metabolites of these amines, showed no or 
no significant differences between the groups. 
M E A N V A L U E S 0 F 5 - H T 
NG/ML CSF 
70 T 
S = SUICIDES 
C = CONTROLS 
60 --
50 -• 
Fig. 3. Serotonin concentrations 
in cranial and lumbar CSF of 
suicide victims and controls s c s c CRANIAL LUMBAR 
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RELATIVE FREQUENCY DISTRIBUTION CF 5-HT LEVELS IN CSF 
L U M 8 A R 
C 0 N T R 0 L : 
N s 13 
RELATIVE FREQUENCY DISTRIBUTION CF 5-HT LEVELS IN CSF 
C R A N I A L 
C O N T R O L S 
N = 37 
MG/ML CSF 
S U I C I D E S 
N s 22 
NG/ML CSF 
S U I C I O E S 
N > 46 
NG/ML CSF 
Fig. 4. Distribution of relative frequency of Fig. 5. Distribution of relative frequency of 
the cranial Serotonin concentrations in suicide the lumbar Serotonin concentrations in suicide 
victims and controls victims and controls 
Discussion 
Postmortem biochemical investigations of mental disorders often are regarded 
with Skepsis by some clinicians because of potential artifacts. In fact, for many 
endogenous Substrates there is evidence for postmortem alterations, e.g., be-
cause of sustained enzymatic activities. Table 3 lists some possible factors of in-
fluence on CSF of biogenic amines. 
The most often discussed and greatest factor of influence is believed to be 
the postmortem delay, which either may include an enzymatic activity within 
the pathway or a chemical degradation process of the amines. However, we 
could not find any correlation between postmortem delay and the concentra-
tions, for instance, of 5-HT and/or norepinephrine (Fig. 6), although we have 
to make one limitation: we were not able to observe the time immediately after 
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Fig. 6. Postmortem interval 
(= time elapsed between time 
of death or discovery of the 
corpse and autopsy) vs cranial 
CSF Serotonin and norepi-
nephrine concentrations of 
both suicide victims and 
controls. NE, norepinephrine; 
5-HT, Serotonin 
NG/ML 
6 0 + 
2 0 
10 
o = NE 
* = 5-HT 
4 0 6 0 8 0 1 0 0 
postmortem interval (hours) 
1 2 0 
Table 3. Theoretical and practical aspects of factors influencing postmortem biogenic amine 
levels in CSF 
1. Postmortem delay 
2. Duration of death agony 
3. Handling of the corpse 
4. Previous drug treatment 
5. Age, sex, height, weight 
6. Chemical stability 
7. Sampling technique 
8. Seasonal/diurnal rhythms 
death. The duration of agony may influenae the amine levels. We were able to 
find in previous investigations of peripheral postmortem blood that cat-
echolamines are extremely high in prolonged agony (Kauert 1986). If that 
would be the case, however, we must assume that people committing suicide 
respond more powerfully to agonal stress than those who died without any in-
tention. 
The position of the corpse and its handling before autopsy are potential fac-
tors influencing the biogenic amine levels, particularly in regard to the cra-
niocaudal gradient of concentration. One would expect that an equilibration 
process during transfer of the corpse may occur. On the other hand, from our 
results we were able to show a marked gradient between cranial and lumbar 
CSF levels of 5-HT (Fig. 7). Because of the involvement of 5-HT in dark-light-
dependent pathways of the pineal gland hormone melatonin, an influence of 
this biorhythm on CSF 5-HT was thought to exist by Asberg (personal com-
munication, 1985). Taylor et al. (1985) reported about diurnal rhythms of Sero-
tonin in Rhesus monkey CSF rising at the beginning of the dark period and 
falling to base line at the appearance of light. However, the authors mentioned 
that there is a marked Variation in the amplitude of the Serotonin elevations. 
We therefore examined a possible influence of biorhythms on our results and 
plotted the levels of cranial and lumbar CSF vs clock t ime of death so far as 
this was possible (Fig. 8). Only those cases are illustrated in Fig. 8 for which we 
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N G / M L C S F 
Fig. 7. Postmortem craniocaudal gradient of CSF 
Serotonin concentra t ions . S, Suboccipital; L, lumbar 
, CSF 
S L 5-HT 
have nearly exact time data, and there were no hints of any correlation between 
dark-light periods and 5-HT levels, either in cranial or in lumbar CSF. Beyond 
that, there is no evidence that suicides are preferably committed at night. 
On examination of all factors we have discussed, we now have to take into 
account that all but a previous drug treatment, especially with antidepressives, 
have to be referred to both suicide victims and controls so that none of these 
factors gives an explanation for the differences of 5-HT levels in CSF of 
suicides and controls. The demographic data for both collectives listed in Ta-
ble 2a, b do not differ with the exception of postmortem delay, which is shorter 
in suicide cases because autopsies are performed as soon as possible after dis-
covery for criminalistic investigations. 
What can we conclude from our studies up to now? First of all, we may sug-
gest that in suicide cases a deficit of 5-HT does not exist at least in CSF. In con-
trast, some authors reported decreased postmortem 5-HT levels in specific brain 
sections (Lloyd et al. 1974; Korpi et al. 1983; Pare et al. 1969). We are presently 
not able to confirm whether or not these observations are perhaps negatively 
correlated with our findings. A decreased monoamine oxidase activity, as ob-
served by some authors in suicidal behavior and suicides with previous alcohol-
ism, does not seem to be responsible for our findings when we keep in mind the 
results of increased 5-HIAA levels in suicides reported by Arato (1986). 
It might be that suicide has its own nosologic criteria, which are in-
dependent of mental disorders; however, up to now we are not able to give an 
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5-HT LEVELS IN CSF VS TIME GF DAY 
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5-HT LEVELS IN CSF VS TIME OF DAY 
L U M B A R 
NG/ML CSF 
60 -
1 L A 
CONTROLS 
12 2 4. 6 8 10 12 2 4- 6 
" NIGHT PERIOD " 
I 10 12 
TIHE OF DAY 
NG/ML CSF 
T, T, t , 10 12 2 4- 6 8 10 12 







JJ 12 2 + 6 8 10 12 2 4- 6 8 10 12 
, , TIHE OF DAY 
M
 NIGHT PERIOD " 
12 2 4- 6 8 10 12 2 
" NIGHT PERIOD
 M 
8 10 12 
, TIME OF DAY 
Fig. 8a, b. Distribution of Serotonin levels in cranial (a) and lumbar (b) CSF vs time of day 
explanation for our findings with regard to the monoamine hypothesis of de-
pressive disorders. Many potential influences, e.g., drugs and poisons on Serot-
onin turnover, remain to be clarified which is why we are going to enlarge the 
number of cases to obtain sufficient collectives for Statistical work. For forensic 
purposes as mentioned at the beginning of our paper, we are hopeful of having 
available a biochemical marker for differentiation between suicide and nonsui-
cide. 
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